advertisement
Advertisement (image not found)

Clinical Trials

Page
12345›»

Novelos Therapeutics, Inc. (NVLT) Discontinues Current Development Program For NOV-002 In NSCLC; Primary And Secondary Endpoints Not Met In Phase 3 Trial

Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biopharmaceutical company...

Thursday, March 18, 2010 Source: BUSINESS WIRE

Protalix Initiates A Phase I Clinical Trial Of Acetylcholinesterase For Biodefense Indications

Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has...

Wednesday, March 17, 2010 Source: Protalix BioTherapeutics, Inc.

Single Short Course Of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function

Tolerx, Inc., today announced the publication in Diabetologia, the journal of...

Tuesday, March 16, 2010 Source: Tolerx, Inc.

Nuvo Research Enrolls First Patient In Phase 2 WF10 Allergic Rhinitis Trial

Nuvo Research Inc. , a Canadian drug development company focused on the research...

Monday, March 15, 2010 Source: Nuvo Research Inc.

PERSEUS Trial Results Demonstrate Positive Safety And Efficacy Outcomes For Boston Scientific's Novel Platinum Chromium TAXUS® Element? Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS...

Monday, March 15, 2010 Source: Boston Scientific Corporation

Abbott Announces Positive Data From ABSORB Trial On Its Bioresorbable Vascular Scaffold Technology

Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial...

Monday, March 15, 2010 Source: Abbott

TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing In Diabetic Foot Infection Met Primary Endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin...

Friday, March 12, 2010 Source: TaiGen Biotechnology Co., Ltd.

TaiGen Biotechnology Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing In Diabetic Foot Infection Met Primary Endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin...

Friday, March 12, 2010 Source: PRNewswire

Pfizer Inc. (PFE) (JOBS) Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO...

Friday, March 12, 2010 Source: BUSINESS WIRE

Study Reinforces Role Of AED Vimpat (lacosamide) (C-V) As Add-On Treatment For POS

Atlanta – March 11, 2010 – press release – UCB today announced that the antiepileptic...

Friday, March 12, 2010 Source: University of Minnesota
Page
12345›»

News Search

Search News By Keywords

News Sections

New Technologies

High Quality Antibodies
High Quality Antibodies
from Randox Laboratories Ltd.
IHC-plus(tm) Antibodies for Immunohistochemistry
IHC-plus™ Antibodies for...
from LifeSpan BioSciences
More New Technologies
advertisement
Advertisement (image not found)

Email Newsletter Sign-Up

Stay updated on the latest technologies and news with Biocompare's newsletters
(See samples here)






 Select All

Privacy Policy | Manage Subscriptions

Loading

Loading